ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00479674

Public ClinicalTrials.gov record NCT00479674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer

Study identification

NCT ID
NCT00479674
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Duke University
Other
Enrollment
41 participants

Conditions and interventions

Conditions

Interventions

  • Abraxane Drug
  • Bevacizumab Drug
  • Carboplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2007
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update posted
Feb 17, 2015

2007 – 2014

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
4
Facility City State ZIP Site status
Presbyterian Health Care Charlotte North Carolina 28204
Northeast Oncology Associates Concord North Carolina 28205
Duke University Medical Center Durham North Carolina 27710
Forsyth Regional Cancer Center Winston-Salem North Carolina 27103-3019

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00479674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2015 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00479674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →